Companies Savara Inc
Savara (SVRA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Savara Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers60th pct.Of 10 peer CEOs
CEO pay, last three years
- $3,759,723FY2023
- $4,912,011FY2024
- $4,845,000FY2025
CEO total pay was $4,845,000 in fiscal 2025, down from $4,912,011 in fiscal 2024.
FY2025: salary $660,000 · bonus $0 · stock awards $3,870,000 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Savara Inc in fiscal 2025?
As disclosed, Matthew Pauls (Chair of the Board of Directors and Chief Executive Officer) was the highest-paid executive at Savara Inc in fiscal 2025, with total compensation of $4,845,000.
How does Savara Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Matthew Pauls's total compensation ranked at the 60th percentile of Savara Inc's disclosed peer group.
What is Savara Inc's CEO-to-median employee pay ratio?
As disclosed, Savara Inc's CEO-to-median employee pay ratio was 9.3:1.
How did shareholders vote on Savara Inc's executive compensation?
As disclosed, 98.43% of shareholders supported Savara Inc's executive compensation in the latest say-on-pay vote.
How much does Savara Inc spend in total on board compensation for fiscal 2025?
As disclosed, Savara Inc reported total board compensation of $1,608,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Matthew Pauls | $660,000 | $0 | $3,870,000 | $0 | $297,000 | $0 | $18,000 | $4,845,000 |
| Chair of the Board of Directors and Chief Executive Officer | ||||||||
| Yasmine Wasfi | 476,728 | 0 | 1,691,850 | 246,742 | 186,850 | 0 | 18,000 | 2,620,170 |
| Chief Medical Officer | ||||||||
| David Lowrance | 471,000 | 0 | 1,612,500 | 0 | 176,625 | 0 | 18,000 | 2,278,125 |
| Chief Financial & Administrative Officer and Secretary | ||||||||
| Robert Lutz | 471,000 | 0 | 1,612,500 | 0 | 176,625 | 0 | 18,000 | 2,278,125 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Matthew Pauls | $4,845,000 | $4,912,011 | $3,759,723 | ↓ −67,011 |
| Yasmine Wasfi | 2,620,170 | — | — | — |
| David Lowrance | 2,278,125 | 1,872,628 | 1,519,354 | ↑ +405,497 |
| Robert Lutz | 2,278,125 | 1,871,788 | 2,664,280 | ↑ +406,337 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is intended to attract and retain qualified executive officers and to align the interests of our executive officers with those of our stockholders by incentivizing and rewarding achievement of business objectives that will enhance Savara's value and by promoting commitment to long-term success.
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Yasmine Wasfi | OPTION | 2025-10-20 | — | — | 70,000 | — | $246,742 |
| Yasmine Wasfi | RSU | 2025-12-09 | — | — | 240,000 | — | 1,548,592 |
| Robert Lutz | RSU | 2025-12-09 | — | — | 250,000 | — | 1,612,500 |
| David Lowrance | RSU | 2025-12-09 | — | — | 250,000 | — | 1,612,500 |
| Matthew Pauls | RSU | 2025-12-09 | — | — | 600,000 | — | 3,870,000 |
| Yasmine Wasfi | RSU | 2025-10-20 | — | — | 35,000 | — | 143,850 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Yasmine Wasfi | $1,692,442 | $0 | $246,742 | 0.0% |
| Robert Lutz | 1,612,500 | 0 | 0 | 0.0% |
| David Lowrance | 1,612,500 | 0 | 0 | 0.0% |
| Matthew Pauls | 3,870,000 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Lutz | Option | 20,000 | 4.45 | — |
| David Lowrance | Option | 20,000 | 4.45 | — |
| Yasmine Wasfi | RSU | 35,000 | — | 211,050 |
| Yasmine Wasfi | Option | 55,000 | 4.13 | — |
| David Lowrance | Option | 62,500 | 1.51 | — |
| Yasmine Wasfi | Option | 70,000 | 4.11 | — |
| Yasmine Wasfi | RSU | 75,000 | — | 452,250 |
| Robert Lutz | RSU | 100,000 | — | 603,000 |
| David Lowrance | RSU | 100,000 | — | 603,000 |
| Robert Lutz | Option | 109,375 | 2.53 | — |
| Matthew Pauls | Option | 112,500 | 4.45 | — |
| Yasmine Wasfi | Option | 131,250 | 3.35 | — |
| Matthew Pauls | Option | 175,000 | 1.51 | — |
| Robert Lutz | Option | 225,000 | 3.35 | — |
| David Lowrance | Option | 225,000 | 3.35 | — |
| Yasmine Wasfi | RSU | 240,000 | — | 1,447,200 |
| Robert Lutz | RSU | 250,000 | — | 1,507,500 |
| David Lowrance | RSU | 250,000 | — | 1,507,500 |
| Matthew Pauls | RSU | 400,000 | — | 2,412,000 |
| Matthew Pauls | RSU | 600,000 | — | 3,618,000 |
| Matthew Pauls | Option | 675,000 | 3.35 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joseph S. McCrackenIndependent · Lead Independent Director · Compensation · Nominating/Governance (Chair) | $87,000 | $258,000 | $0 | $0 | $0 | $345,000 |
| David A. RamsayIndependent · Audit (Chair) · Nominating/Governance | 65,000 | 258,000 | 0 | 0 | 0 | 323,000 |
| Nevan ElamIndependent · Compensation (Chair) · Nominating/Governance | 59,000 | 258,000 | 0 | 0 | 0 | 317,000 |
| An van Es-JohanssonIndependent · Audit · Compensation | 57,000 | 258,000 | 0 | 0 | 0 | 315,000 |
| Richard J. HawkinsIndependent · Audit | 50,000 | 258,000 | 0 | 0 | 0 | 308,000 |
| Matthew PaulsEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $258,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 14,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $318,000 |
| Equity awards (grant-date value) | $1,290,000 |
| All other compensation | $0 |
| Total cost of the board | $1,608,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Savara as a peer
Companies that benchmark against SVRA
6 companies name SVRA as a compensation peer
- Altimmune, Inc.ALTFY2025
- Astria Therapeutics, Inc.ATXSFY2024
- aTYR PHARMA INCATYRFY2025
- Cartesian Therapeutics, Inc.RNACFY2025
- Innoviva, Inc.INVAFY2025
- Trevi Therapeutics, Inc.TRVIFY2025
Each company listed discloses SVRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SVRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
APLT Applied Therapeutics, Inc.KROS Keros Therapeutics, Inc.PLRX Pliant Therapeutics, Inc.ALT Altimmune, Inc.ATXS Astria Therapeutics, Inc.GOSS Gossamer Bio, Inc.FULC Fulcrum Therapeutics, Inc.ABEO Abeona Therapeutics Inc.AMLX Amylyx Pharmaceuticals, Inc.SLNO Soleno Therapeutics, Inc.
Peer reciprocity
The companies Savara Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Soleno Therapeutics, Inc. | 2024 | Anish Bhatnagar | $640,000 | $46,883,000 | $3,231,230 | $403,200 | $51,160,430 |
| 2 | Altimmune, Inc. | 2025 | Vipin Garg | 658,694 | 1,153,600 | 4,812,167 | 357,753 | 8,026,590 |
| 3 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 4 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 5 | Savara Inc | 2025 | Matthew Pauls | 660,000 | 3,870,000 | 0 | 297,000 | 4,845,000 |
| 6 | Abeona Therapeutics Inc. | 2025 | Vishwas Seshadri | 662,000 | 2,472,698 | — | 309,485 | 3,991,516 |
| 7 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 8 | Amylyx Pharmaceuticals, Inc. | 2025 | Joshua Cohen | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 9 | Keros Therapeutics, Inc. | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 10 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 11 | Applied Therapeutics, Inc. | 2024 | Les Funtleyder | 530,625 | 153,000 | 132,000 | 0 | 1,053,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Savara Inc | 90% | RSU 100 | not disclosed | Aon |
| Abeona Therapeutics Inc. | not disclosed | Restricted Stock Awards 100 | not disclosed | Radford, a unit of Aon plc |
| Altimmune, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Amylyx Pharmaceuticals, Inc. | 106.5% | not disclosed | No | Pearl Meyer |
| Applied Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | AON Radford Global Compensation Consulting |
| Astria Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Keros Therapeutics, Inc. | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Pliant Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Soleno Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon plc |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 156,706,529 | 2,307,296 | 195,253 | 98.43% | Passed |
| 2025 | 2025-06-05 | 120,600,997 | 3,297,958 | 137,189 | 97.34% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 98.43%a |
| 2025 | 2025-06-05 | 97.34%b |
a. Approved under the standard stated in the filing — “An abstention will have the same effect as a negative vote.”.
b. Approved under the standard stated in the filing — “Neither abstentions nor broker non-votes will be counted toward the vote total and therefore will have no effect on the outcome of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 9.3 : 1 |
|---|---|
| CEO total compensation | $4,845,000 |
| Median employee compensation | $519,951 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 60,057 | $6 | $330,314 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 129,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 53,387 | 6 | 293,629 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 87,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 56,937 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 10,114 | 6 | 55,627 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | A | 218,750 | 2 | 330,313 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 28,928 | 6 | 159,104 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | A | 87,650 | 3 | 293,628 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 21,682 | 6 | 119,251 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 218,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 394,528 | 6 | 2,241,432 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | A | 12,500 | 4 | 55,625 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | D | 11,491 | 6 | 63,201 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | A | 56,937 | 1 | 63,200 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | A | 129,350 | 1 | 159,101 | Common | Form 4 ↗ |
| David Lowrance | Chief Financial Officer | 2026-06-22 | A | 75,000 | 2 | 119,250 | Common | Form 4 ↗ |
| Robert Lutz | Chief Fin. & Operating Officer | 2026-07-15 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Robert Lutz | Chief Fin. & Operating Officer | 2026-07-15 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Braden C. Parker | Chief Commercial Officer | 2026-09-24 | D | 29,323 | 5 | 148,668 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (57 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Matthew Pauls. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 33. As printed: 4,845,000. View filing ↗
- Section 01, Yasmine Wasfi. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table”. As printed: 2,620,170. View filing ↗
- Section 01, David Lowrance. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table”. As printed: 2,278,125. View filing ↗
- Section 01, Robert Lutz. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table”. As printed: 2,278,125. View filing ↗
- Section 03, Yasmine Wasfi OPTION. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Yasmine Wasfi RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Lutz RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Lowrance RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Pauls RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Yasmine Wasfi RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 9.3 : 1. View filing ↗
- Section 08, Joseph S. McCracken. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 345,000. View filing ↗
- Section 08, David A. Ramsay. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 323,000. View filing ↗
- Section 08, Nevan Elam. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 317,000. View filing ↗
- Section 08, An van Es-Johansson. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 315,000. View filing ↗
- Section 08, Richard J. Hawkins. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 308,000. View filing ↗
- Section 08, Matthew Pauls. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Lowrance 2026-06-22. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Lutz 2026-07-15. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Lutz 2026-07-15. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Braden C. Parker 2026-09-24. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-08. Item 5.07 · say-on-pay result. As reported: 98.43% (votes for as printed: 156,706,529). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-06. Item 5.07 · say-on-pay result. As reported: 97.34% (votes for as printed: 120,600,997). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 318,000 + equity 1,290,000 + all other 0 = 1,608,000, summed across the director compensation table rows.
- Soleno Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-22. CEO total compensation as printed in Soleno Therapeutics, Inc.'s own proxy. As printed: 51,160,430. View filing ↗
- Altimmune, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-17. CEO total compensation as printed in Altimmune, Inc.'s own proxy. As printed: 8,026,590. View filing ↗
- Astria Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. View filing ↗
- Pliant Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. View filing ↗
- Savara Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara Inc's own proxy. As printed: 4,845,000. View filing ↗
- Abeona Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Abeona Therapeutics Inc.'s own proxy. As printed: 3,991,516. View filing ↗
- Fulcrum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗
- Amylyx Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Amylyx Pharmaceuticals, Inc.'s own proxy. As printed: 2,719,807. View filing ↗
- Keros Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics, Inc.'s own proxy. As printed: 2,540,204. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Applied Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Applied Therapeutics, Inc.'s own proxy. As printed: 1,053,846. View filing ↗
- Section 10a, Altimmune, Inc. reciprocity. DEF 14A. Altimmune, Inc. names Savara Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Astria Therapeutics, Inc. reciprocity. DEF 14A. Astria Therapeutics, Inc. names Savara Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗